

**DRUG UTILIZATION REVIEW BOARD**

**October 19, 2011**

**201 West Capitol Ave, Hearing Room 2, Jefferson City, MO 65101**

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, PharmD  
Charlene Heyde, RPh  
Sandra Bollinger, PharmD  
Kenneth Haller, MD  
Glenn Talboy, MD  
Jennifer Passanise, ANCC-BC, FNP

**DUR BOARD MEMBERS ABSENT**

Stacy Mangum, PharmD  
Kirk Nelson, MD  
Ginger Nicol, MD  
Randy Beckner, PharmD

**OTHERS IN ATTENDANCE**

Nick Boyer, Astra Zeneca  
Suzanne Goot, Abbott  
Eric Blake, Merck  
M. Patty Laster, Astellas  
Jared Lurk, Novartis

Dean Groth, Pfizer  
Mike Kloos, Pfizer  
Debbie King, Amgen  
Susan Zalenski, J&J  
Lon Lowery, Novartis

**MHD STAFF PRESENT**

Rhonda Driver, RPh, Director of Pharmacy  
Mark Roaseau, RPh, Clinical Pharmacist  
Tasia Roberts, Senior Office Support Asst.  
Jenna Twehus, RN  
Ashley Wilson, DUR Coordinator  
Andrew Haslag, Fiscal Manager  
Jayne Zemmer, Program Manager  
Katherine Hinkle-Black, Correspondence and Information Specialist  
Angela Wilson, Pharmacy Unit Supervisor

**CONTRACTED STAFF PRESENT**

Jennifer Kemp-Cornelius, PharmD, ACS Healthcare  
Geri Roling, RN, Wipro (Formerly Infocrossing Healthcare)  
Annette Walther, Wipro (Formerly Infocrossing Healthcare)

Andy Becker, BI  
Dave Sproat, BMS  
Walter Serafin, EiSai  
Maureen Bresselt, BI

Hank Lavellet, Forest  
Stephanie Keithly, Novo Nordisk  
Scott Edelhouser, Alcon  
Eric Gardner, Vertex

\*Many names on the sign in sheet were illegible. Sign in sheet on file for review.

<b>Welcome, Introductions and Opening Remarks</b>	Acting Chairman, Susan Abdel-Rahman, PharmD, called the meeting to order at approximately 10:15 a.m. A quorum was established. Rhonda Driver, RPh, Director of Pharmacy, facilitated the meeting on behalf of the MO HealthNet Division (MHD). Ms. Driver instructed that MO HealthNet Division will be at their new location by October 24, 2011, located at 615 Howerton Court. Ashley Wilson was welcomed as the new DUR Coordinator, replacing Tisha McGowan.
<b>Minutes Approval</b>	Minutes of the July 2011 meeting were reviewed and approved as submitted.
<b>Pharmacy Program/Budget Update</b>	Andrew Haslag, Fiscal Manager reported the Division is about 3 months into FY12 and the budget looks favorable. The budget for FY13 was submitted to the Governor's office around October 1, 2011. Mr. Haslag reported the budget for FY13 is still looking tight. No other changes have been submitted.
<b>Review of Prior Authorization Meeting:</b>	Copies of the agenda and draft minutes, including public hearing, from the September 15, 2011 <i>Drug Prior Authorization Committee Meeting</i> were included in the members' meeting packet.
<b>Implementation Schedule</b>	An updated copy of the <i>Proposed Implementation Schedule for Edits</i> , including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The schedule had been updated with all edits approved at the last quarter's meetings which included and annual PDL implementation. This schedule may be found on the MHD web page at <a href="http://dss.missouri.gov/mhd/cs/pharmacy/pdf/impsched.pdf">http://dss.missouri.gov/mhd/cs/pharmacy/pdf/impsched.pdf</a>
<b>New Drug Review</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> - Drug monographs were available for review at <a href="http://www.heritage-info.com/mocaidrx">http://www.heritage-info.com/mocaidrx</a> for all new products reviewed this quarter (Identified by First Data Bank in April, May, and June 2011). A listing of products recommended for open access, clinical edit, as a PDL product or for continued prior authorization was provided in the Members' meeting packet for discussion and action. This listing was also provided as a handout (see meeting packet) to all attending. Ms. Driver reviewed the MHD recommendations for products whose review was completed this quarter.</li> <li>• <b>Decision</b> – In the interest of time the Board agreed to block these and the Preferred Drug List (PDL) recommendations into one inclusive vote, pulling out any issues that might require separate discussion. New Drug recommendations were included in this block vote and approved as submitted. (See Roll Call Vote)</li> </ul>
<b>Preferred Drug List (PDL)</b>	Products and classes under review this quarter have existing contracts through December 31, 2011. Recommended changes to the edits were bolded for easy identification.
<b>Ace Inhibitors</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, stating no changes within this class. Generics first.</li> <li>• <b>Decision</b> – In the interest of time the Board agreed to block recommendations into one inclusive vote, pulling out any issues that might require separate discussion. This Preferred Drug List (PDL) was included in the block vote and approved as submitted. (See Roll Call Vote)</li> </ul>
<b>Ace Inhibitors/Diuretic Combination</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, stating no changes within this class. Generics first.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>

<b>Ace Inhibitor/Calcium Channel Blocker Combination</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria, stating both of the brand name products have been supported through the supplemental process. Recommending them for preferred status with their generic counterparts being non-preferred.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.(See Roll Call Votes)</li> </ul>
<b>Alpha-Glucosidase Inhibitors</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document pointing out Precose® will be moving to the Preferred side, and generic Acarbose being recommended non-preferred.</li> <li>• <b>Decision</b> - This PDL recommendation was accepted as presented and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Alzheimer's Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. Rivastigmine recommended as non-preferred, with 3 branded products as preferred agents.</li> <li>• <b>Decision</b> - This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Angiotensin Receptor Blocker</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. New product introduced into this class, Edarbi®, recommended as non-preferred. Cozaar® moved to non-preferred with the branded items left as preferred. Losartan replaces branded Cozaar®.</li> <li>• <b>Decision</b> - This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Angiotensin Receptor Blocker/Diuretic Combination</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, stating that Hyzaar® will be non-preferred, with the Losartan HCTZ being preferred.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Antidiabetic Combination Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. A new product introduced to this class, Kombiglyze® XR, recommending for preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Antihyperuricemics</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document noting Uloric® is the only non-preferred agent in this class. No changes were recommended.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Biguanides</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document noting generics first edit with no change, Metformin, with the immediate and extended release are the preferred agents.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Bile Salts</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting the capsules are preferred and the tablets are non-preferred.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.</li> </ul>
<b>Bone Ossification</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document noting the Boniva tablets are now being</li> </ul>

<b>Suppression Agents/Calcitonins</b>	recommended for preferred status and new product Atelvia® being recommended as non-preferred. <ul style="list-style-type: none"> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Cryptin Associated Periodic Syndrome Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document noting no changes.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Direct Renin Inhibitor &amp; Combinations</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria. Tekamlo® is the only non-preferred agent.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Electrolyte Depleters</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. New products Fosrenol® and Phoslyra® both recommended as non-preferred. Phoslo® and Renagel® are both recommended as preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Fibromyalgia Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria. The current clinical criteria remains in place.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Herpes Antivirals</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Immunomodulators/RA Agents (DMARDs)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, and noted new drug, Amevive® be recommended for non-preferred status. No other changes.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Inhaled Antibiotics</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting Cayston® is being recommended as non-preferred, Tobii® is the preferred agent.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Intranasal Antihistamines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, stating Azelastine Nasal product is recommended as non-preferred, brand name items being recommended as preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Leukotriene Modifiers</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call</li> </ul>

	Votes)
<b>Lipotropics-Niacin Preparations</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Low Sedating Antihistamines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. Recommending Cetirizine OTC Chew Tabs as non-preferred, while Loratadine OTC Chew Tabs and Cetirizine Rx Syrup are being recommended as preferred. OTC or Rx brand name products being recommended as non-preferred agents, with the exception on Levocetirizine Tabs, which is the generic for Clarinex®.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Low Sedating Antihistamines/Decongestant Combinations</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Macrolides Adult</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. E.E.S. 400® is recommended as preferred, and Ery-Tab® being recommended as non-preferred.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Macrolides Pediatric</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. E.E.S. 200 Suspension and ZMax Suspension are both recommended as non-preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Meglitinides</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Multiple Sclerosis Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. Gilenya® is recommended for non-preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Narcotics: Long Acting</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. New product, Brutrans® Transdermal, recommended for non-preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Nasal Steroids</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call</li> </ul>

	Votes)
<b>Ophthalmic Antihistamines</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting Alrex, Optivar, Epinastine, and Lastacaft are recommended for non-preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Ophthalmic Mast Cell Stabilizers</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Ophthalmic Prostaglandin Agonists</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting Xalatan® and Lumigan® are recommended for non-preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Ophthalmic Quinolones</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, stating Moxeza® is a recommended preferred new product and Zymaxid® is recommended as non-preferred.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Otic Quinolones</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Pancreatic Enzymes</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, stating Pancreaze® is recommended for non-preferred status and Zenpep® being recommended for preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Pulmonary Hypertension Agents (Oral/Inhaled/Injectable)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting Letairis® is recommended for preferred status and Tracleer® being recommended for non-preferred status. Veletri® is a new product recommended for non-preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Quinolones-Systemic</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting Levofloxacin is recommended for preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>2<sup>nd</sup> Generation Sulfonylureas</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>

<b>Self-Injectable Epinephrine Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting Epinephrine (injection) along with EpiPen® are a preferred agent.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Serotonin Receptor Agonists (Triptans)</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting Treximet®, Cambia® and Sumavel® are recommended changes as non-preferred. Treximet® is being changed from preferred to non-preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Thiazolidinediones</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting Actos® and Avandia® are both preferred agents.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Topical Agents for Psoriasis</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting Clobeta® + Plus Kit and Calcitrene are both recommended as non-preferred; Dovonex® recommended as preferred.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Topical Retinoids</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting Differin® Cream is recommended as preferred, all other products including new product Veltin® is recommended for non-preferred status.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Tramadol Agents</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document, noting Tramadol ER is recommended as non-preferred.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Ulcerative Colitis Agents/Oral &amp; Rectal</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>Vaginal Antibiotics</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Ms. Driver reviewed the criteria document. No changes were recommended to the current PDL criteria.</li> <li>• <b>Decision</b> – This PDL recommendation was accepted and added to the block vote.( See Roll Call Votes)</li> </ul>
<b>ACS Healthcare Update</b>	Jennifer Kemp-Cornelius, PharmD Jennifer Kemp-Cornelius, PharmD, presented 2 proposals for the next population based intervention mailing; Polypharmacy and Hyperlipidemia. Both proposals were approved to be mailed.
<b>Preferred Drug List Discussion/Therapeutic</b>	A handout of therapeutic categories to be considered for inclusion on the PDL for the next quarter and meeting was provided in the meeting packet and to all attendees. These categories will be an annual

<b>Classes</b>	review of products with contracts expiring December 31, 2011. The Division will also post these classes to the Web page.
<b>Program Statistics:</b>	
<b>Top 25 Drugs by Cost</b>	No changes were available for this meeting.
<b>Clinical Edit Summary Report</b>	An overview report of the clinical edit and prior authorization request transaction counts for the month of August 2011 provided for all attending. The report detailed total transaction counts as well information on the outcome (approval or denial) of the request.
<b>Call Center Statistics</b>	A handout illustrating pharmacy help desk call center activity was provided for all attending. Statistics for October 1, 2009 to July 31, 2011. Also included for the Boards' information was a CyberAccess™ Report. This report detailed statistics for CyberAccess™ usage from April 2006 through August 2011 and showed how usage has grown overtime and as edits are implemented. It was noted the most recent growth in CyberAccess users was in the Home and Community Based Waiver provider types.
<b>Program Utilization Information/Other Business</b>	During the next few months the Department and Division plan to work to fill the various vacancies on the Division's advisory groups including this Committee and the DUR Board. Clinical Services will be moving to 615 Howerton Court to unite the Division under one roof. Attendees were advised to check the <a href="#">calendar of events</a> on the MHD website for meeting location changes over the next few months as MHD works to find appropriate meeting space which is not available at the Howerton Court location at this time.
<b>Adjourn</b>	The DUR Board went into Executive Session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See attached roll call vote). The next meeting is scheduled for January 18, 2012.



### Roll Call Votes – October 19, 2011

<b>Member</b>	<b><i>All Recommendations Block Vote</i></b>	<b><i>Closed Session</i></b>	<b><i>Adjourn</i></b>
Susan Abdel-Rahman	<i>Yeah</i>	Yeah	Yeah
Randy Beckner	Absent	Absent	Absent
Sandra Bollinger	<b>Motion</b>	<b>Motion</b>	Yeah
Kenneth Haller	Yeah	Yeah	Yeah
Charlene Heyde	Yeah	Yeah	Yeah
Stacy Mangum	Absent	Absent	Absent
Kirk Nelson	Absent	Absent	Absent
Ginger Nicol	Absent	Absent	Absent
Jennifer Passanise	<b>Second</b>	<b>Second</b>	Yeah
Glenn Talboy	Yeah	Yeah	Yeah

**EXECUTIVE SESSION**

October 19, 2011

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, PharmD  
Charlene Heyde, RPh  
Sandra Bollinger, PharmD  
Kenneth Haller, MD  
Glenn Talboy, MD  
Jennifer Passanise, ANCC-BC, FNP

**DUR BOARD MEMBERS ABSENT**

Stacy Mangum, PharmD  
Kirk Nelson, MD  
Ginger Nicol, MD  
Randy Beckner, PharmD

**MHD STAFF PRESENT**

Rhonda Driver, RPh, Director of Pharmacy  
Mark Roaseau, RPh, Clinical Pharmacist  
Tasia Roberts, Senior Office Support Asst.  
Jenna Twehus, RN  
Ashley Wilson, DUR Coordinator  
Andrew Haslag, Fiscal Manager  
Jayne Zemmer, Program Manager  
Katherine Hinkle-Black, Correspondence and Information Specialist  
Angela Wilson, Pharmacy Unit Supervisor

**CONTRACTED STAFF PRESENT**

Jennifer Kemp-Cornelius, PharmD, ACS Healthcare  
Geri Roling, RN, Wipro (Formerly Infocrossing Healthcare)  
Annette Walther, Wipro (Formerly Infocrossing Healthcare)

Minutes Review	Minutes of the July Executive Session were approved as submitted
Case Reviews	Jenna Twehus, RN presented two handouts that detailed provider summary results and benchmark data for patients being prescribed large amounts of narcotics. The discussion included why these 2 patients were being prescribed high dosages and multiple narcotics. The board decided to do further research to get more information on these issues. No other issues were discussed.
Adjourn	Executive session adjourned at approximately 12:30 p.m. (See roll call vote)